Protective effect of caffeine against cyclophospha mide induced in vivo genotoxicity

Prakash G; Ingle A D; Hosetti B B

doi:10.48165/jlas.2019.1.1.12

Authors

Prakash G Associate Research Scientist, DSA, Toxicology, Advinus Therapeutics Ltd., Bangalore Author
Ingle A D Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Kharghar, Navi Mumbai- 410 210, MS, India. Author
Hosetti B B Department of Applied Zoology, Kuvempu University, Shankaraghatta, 577 451, Karnataka, India. Author

DOI:

https://doi.org/10.48165/jlas.2019.1.1.12

Keywords:

caffeine, chromosomal aberration, cyclophosphamide, cytogenotoxicity, mitotic index

Abstract

Cyclophosphamide is a DNA non-intercalating agent with wide application against several human neoplasms. It is found that caffeine alters protection against cytogenotoxicity of different chemicals and physical mutagens including cyclophosphamide. Modulation of the clastogenic induced effect of cyclophosphamide by three different doses of caffeine (25, 50 and 100 mg/kg) was assessed through the chromosomal aberration and mitotic index studies in bone marrow cells. Micronucleus level were decreased significantly (28.8%) in 100 mg caffeine treated group at 30 h post treatment. Results revealed that caffeine decreased the cyclophosphamide induced chromosomal aberration and mitotic index in bone marrow cells. In the present study, the percentage of dividing cells were reduced more in the mice pre-treated with CAF at the dose rate of 100 mg/kg than with lower doses of CAF in all the three anticancer drugs tested. Thus, CAF modulation is expected to play an important role in the development of cancer chemotherapy. The protective effect of caffeine was found to be dose dependent. However, further study on the mechanism of quenching of free radicals and induction of apoptosis by caffeine are required to substantiate the results.

Downloads

Download data is not yet available.

References

Abrahm SK (1989). Inhibition of in vivo genotoxcity by coffee. Food Chem. Toxicol. 27:787- 792.

Abrahm SK (1991). Inhibitory effects of coffee in the genotoxcity of carcinogens in mice. Mutat. Res. 262:109- 114.

Aeschbcher HU, Jaccud E (1990). Inhibition by coffee of nitrosaurea-mediated DNA damage in mice. Food Chem. Toxicol. 28: 633- 637.

Choudhury RC, Das Misra, Jagadale MB (2000). Cytogenetic toxicity of vincristine. J Environ. Pathol. Toxicol. Oncol. 19(4): 347- 355.

Choudhury RC, Hasan A, Mahanty V (1995). Effects of mercuric chloride on mitotic, meiotic chromosome and sperm in mice. Biologisches zentral Blatt. 114 : 369- 377.

Cragg GM, Newman DJ, Snader KM (1997). Natural products in drug discovery and development. J. Nat. Prod. 12:6052- 6066.

Deplanque G, Geraline J, Man-Bechrel MC, Cazenave JP, Berger JP, Klein-Soyer C (2000). Caffeine and the G2/M block override; a concept resulting a misleading cell kinetic delay, independent of functional P53. Int. J. Cancer. 94: 363- 369.

Devasayagam TPA, Kesavan PC (1996). Radioprotective and antioxidant action of caffeine; mechanistic consideration. Med. J. Exp. Biol. 34: 291- 297.

Devasayagam TPA, Kamath JP, Mohan H, Kesavan PC (1996). Caffeine as an antioxidant; inhibition of lipid peroxidation induced by reactive oxygen species. Biochim. Biophys. Acta. 1282:63-70.

Farnsworth NR, Akerele O, Bingel AS, Soejarto DD, Guo Z (1985). Medicinal plants in therapy. Bull. World Health Organ. 63:1- 965.

Farooqi Z, Kesavan PC (1992). Radioprotection by caffeine pre- and post-treatment in the bone marrow chromosomes of mice given whole-body gamma irradiation. Mutat. Res. 269 (2): 225- 230.

Fernandez MJ, Lopez A, Santa-maria A (2003). Apoptosis induced by different doses of caffeine on Chinese hamster ovary cells. J. AppI. Toxicol. 23 (4): 221- 224.

IARC (1991). Monographs on the evaluation of carcinogenic risks to humans. Coffee, Tea, Mate, Methylxanthines and Methylglyoxal. International Agency for research on cancer, Lyon. Vol 51:513

Kastenbaum MA, Bowman KO (1970). Tables for determining the statistical significance of mutation frequencies. Mutat. Res. 9: 527- 549.

Lee C (2000). Antioxidant ability of caffeine and its metabolites based on the study of oxygen radical absorbing capacity and inhibition of LDL peroxidation. Clinica Chemica Acta. 295:141- 154.

Lown JW, Joshua AV, Chen HH (1982). Reactive oxygen species leading to lipid peroxidation and DNA lesions implicated in the cytotoxic action of certain antitumor antibiotics, In; McBrein, S. C. H., Slater. T. F., (Eds), Free radicals, lipid peroxidation and cancer academic press, London New York. pp 305- 328.

Nehlig A, Debry G (1994). Potential genotoxic, mutagenic and antimutagenic effects of coffee: A review. Mutat. Res.317: 145- 162.

Noda N, Wakasugi H (2001). Cancer and oxidative stress. JMAJ 44(12): 535-539.

Ramesh CC, Anil KP (2004). Modulatory effects of caffeine on methotrexate-induced cytogenotoxicity in mouse bone marrow. Environ. Toxicol. Pharmacol. 15: 79- 85.

Schmid W (1982). The micronucleus test; An in vivo bone marrow method, In: Hsu,T.C.(Ed), cytogenetic assay of environmental mutagens, Oxford and IBH publishing Co., New Delhi. pp 221- 235.

Shi X, Dalal NS, Jam AC (1991). Antioxidant behavior of caffeine: Efficient scavenging of hydroxyl radicals. Food Chem. Toxicol. 29:1- 6.

Srivastava PS (2002). Biotechnological approaches to potential anti-cancerous herbal drugs of the future. Vol .V, Special edition on cancer, Ukaaz Publications, Hyderabad.

Stavric B (1992). An update on research with coffee/caffeine (1989-1990). Food Chem. Toxicol. 30: 533-555.

Traganos F, Kaminska-Eddy B, Darzynkiewicz Z (2008). Caffeine reverses the cytotoxic and cell kinetic effects of Novantrone (mitoxantrone). Cell Prolif. 24: 305- 319.

Tsuchiya H, Yamamoto N, Asada N (2000). Caffeine potentiated radio chemotherapy and function saving surgery for high grade soft tissue sarcoma. Anticancer Res. 20 (3B):2137-2143.

Weijl NI, Hopman GD, Wipkink-Bakker A, Berger (1998). Cisplatin combination of chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann. Oncol. 9:1331-1337.